Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for TransMedics Group Inc. (TMDX:NASDAQ), powered by AI.
TransMedics Group Inc. is currently trading at $75.82. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for TransMedics Group Inc. on Alpha Lenz.
TransMedics Group Inc.'s P/E ratio is 13.5.
“TransMedics Group Inc. trades at a P/E of 13.5 (undervalued) with strong ROE of 54.2%. 3Y revenue CAGR of 86.4% highlights clear growth momentum.”
Ask for details →TransMedics Group Inc. is a medical technology company focused on the commercialization of organ transplant therapy systems. The company has developed the Organ Care System (OCS), a transformative and portable technology that replicates the conditions of the human body to preserve donor organs for transplantation. This system significantly impacts the organ transplant sector by improving the viability and availability of organs through extended preservation and transport periods. TransMedics Group Inc. primarily serves hospitals and transplant centers, addressing the critical global demand for efficient and reliable organ preservation solutions. Headquartered in Andover, Massachusetts, the company plays a pivotal role in enhancing transplant outcomes by increasing the organ pool and reducing wait times for patients. As an innovative leader in the healthcare technology market, TransMedics is critical in bridging clinical needs with cutting-edge solutions to improve patient quality of life.
“TransMedics Group Inc. trades at a P/E of 13.5 (undervalued) with strong ROE of 54.2%. 3Y revenue CAGR of 86.4% highlights clear growth momentum.”
Ask for details →TransMedics Group Inc. (ticker: TMDX) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 728 employees. Market cap is $2.6B.
The current price is $75.82 with a P/E ratio of 13.54x and P/B of 5.45x.
ROE is 54.24% and operating margin is 17.93%. Annual revenue is $605M.